Abstract
Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4–5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aparicio A, Gardner A, Tu Y, Savage A, Berenson J and Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukaemia 12: 220–229
Berenbaum M (1989) What is synergy?. Pharmacol Rev 41: 93–141
Berenson J, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma D, Heffernan M, Seaman J and Knight R (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl J Med 334: 488–493
Berenson JR, Ravera C, Ma P, Deckert F, Sasaki Y, Saeki T, Takashima S, LoRusso P, Goodin S, Seaman J, Schran H and Zhou H (2000) Population Pharmacokinetics (PK) of Zometa. Proc ASCO,
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890–3894
Coxon FP, Benford HL, Russell RG and Rogers MJ (1998) Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54: 631–638
Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL and Bataille R (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14: 2048–2056
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodrnate treatment. New Engl J Med 339: 357–363
Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA and Reska AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133–138
Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analogue, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358–1367
Fromigue O and Body J (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211–2221
Gessner P (1988) A straightforward method for the studyof drug interactions: an isobolographic primer. J Am Coll Toxicol 7: 987–1012
Gorczyca W, Myron R, Melamed and Darzynkiewicz Z (1993) Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: Detection of DNA strand breaks by flow cytometry using the in situ nick translation assay. Toxicol Lett 67: 249–258
Greco WR, Bravo G and Parsons J (1995) The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 47: 331–385
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New Engl J Med 335: 1785–1791
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF (1995) Bisphosphonates promote apotosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478–1487
Kanis JA, Powles T, Paterson AH, McCloskey EV and Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19: 663–667
Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M and Clarke R (1994) Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation and Mr170,000 glycoprotein (gp170) binding studies. Cancer Res 54: 441–447
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ (1998) Nitrogen-containing bishosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581–589
Magnetto S, Boissier S, Delmas PD and Clezardin P (1999) Additive anti-tumour activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83: 263–269
McCloskey EV, Maclennan CM, Drayson MT, Chapman C, Dunn J and Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100: 317–325
O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr and Kohn KW (1997) Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth- inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300
Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59–65
Rogers M, Chilton K, Coxon F, Lawry J, Smith M, Suri S and Russell R (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11: 1482–1491
Saarto T, Blomqvist C, Virkkunen P and Elomaa I (2000) Adjuvant clodronate does not reduce the frequency of skeletal metastases in node-positive breast cancer patients. J Clin Oncol 19: 10–19
Sato M, Grasser W, Endo N, Akins R, Simmons H and Thompson DD (1991) Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095–2105
Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol, 665–672
Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294–5297
Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M and Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846–854
Van der Pluijm G, Vloedgraven H, Van Beek E, Van der Wee-Pals L, Lowik C and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698–705
Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J and O’Shaughnessy J (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621–1629
Wyllie A, Kerr J and Currie A (1980) Cell death: The significance of apoptosis. Int Rev Cytol 68: 251–306
Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M and Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88: (12 Suppl), 2979–2988
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jagdev, S., Coleman, R., Shipman, C. et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84, 1126–1134 (2001). https://doi.org/10.1054/bjoc.2001.1727
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1727
Keywords
This article is cited by
-
Zoledronic acid-loaded cationic methylcellulose polyplex nanoparticles for enhanced gene delivery efficiency and breast cancer cell killing effect
Applied Nanoscience (2022)
-
Effects of ranibizumab and zoledronic acid on endometriosis in a rat model
Archives of Gynecology and Obstetrics (2022)
-
Effects of ranibizumab and zoledronic acid on endometriosis in a rat model
Archives of Gynecology and Obstetrics (2022)
-
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment
Scientific Reports (2020)
-
Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit
Irish Journal of Medical Science (1971 -) (2020)